148 related articles for article (PubMed ID: 33262113)
1. TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation program.
Lambaudie E; Bannier/Braticevic C; Villaron/Goetgheluck C; Zemmour C; Boher JM; Ben Soussan P; Pakradouni J; Brun C; Lopez Almeida L; Marino P
Int J Gynecol Cancer; 2021 Jun; 31(6):920-924. PubMed ID: 33262113
[TBL] [Abstract][Full Text] [Related]
2. The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
Inci MG; Sehouli J; Schnura E; Lee M; Roll S; Reinhold T; Klews J; Kaufner L; Niggemann P; Groeben H; Toelkes J; Reisshauer A; Liebl M; Daehnert E; Zimmermann M; Knappe-Drzikova B; Rolker S; Nunier B; Algharably E; Pirmorady Sehouli A; Zwantleitner L; Krull A; Heitz F; Ataseven B; Chekerov R; Harter P; Schneider S
Int J Gynecol Cancer; 2023 Aug; 33(8):1304-1309. PubMed ID: 37208019
[TBL] [Abstract][Full Text] [Related]
3. CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.
Classe JM; Ferron G; Ouldamer L; Gauthier T; Emambux S; Gladieff L; Dupre PF; Anota A
Int J Gynecol Cancer; 2022 Aug; 32(8):1071-1075. PubMed ID: 35321888
[TBL] [Abstract][Full Text] [Related]
4. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).
Nitecki R; Rauh-Hain JA; Melamed A; Scambia G; Pareja R; Coleman RL; Ramirez PT; Fagotti A
Int J Gynecol Cancer; 2020 Sep; 30(9):1450-1454. PubMed ID: 32690591
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
7. An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial.
Maurer T; von Grundherr J; Patra S; Jaeger A; Becher H; Schmalfeldt B; Zyriax BC; Chang-Claude J
Int J Gynecol Cancer; 2020 Apr; 30(4):541-545. PubMed ID: 31796532
[TBL] [Abstract][Full Text] [Related]
8. A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE).
Díaz-Feijoo B; Agusti N; Sebio R; Sisó M; Carreras-Dieguez N; Domingo S; Díaz-Cambronero O; Torne A; Martinez-Palli G; Arguís MJ
Int J Gynecol Cancer; 2022 Jul; ():. PubMed ID: 35793862
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study.
Tu H; Huang H; Ouyang Y; Liu Q; Xian B; Song K; Chen G; Shen Y; Liu J
Int J Gynecol Cancer; 2021 Jan; 31(1):129-133. PubMed ID: 32522771
[TBL] [Abstract][Full Text] [Related]
10. The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial.
Tully R; Loughney L; Bolger J; Sorensen J; McAnena O; Collins CG; Carroll PA; Arumugasamy M; Murphy TJ; Robb WB;
Trials; 2020 Jul; 21(1):638. PubMed ID: 32660526
[TBL] [Abstract][Full Text] [Related]
11. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
12. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.
Onda T; Tanaka YO; Kitai S; Manabe T; Ishikawa M; Hasumi Y; Miyamoto K; Ogawa G; Satoh T; Saito T; Kasamatsu T; Nakanishi T;
Jpn J Clin Oncol; 2021 Feb; 51(2):205-212. PubMed ID: 33556170
[TBL] [Abstract][Full Text] [Related]
13. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
15. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
16. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
17. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
18. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
19. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
